Cargando…
Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data
Switching inhalation devices is a reasonable option if problems with control, adherence, or inhalation technique occur in patients with asthma treated with inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA). However, evidence to determine the extent to which the carefully monitored period pe...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560144/ https://www.ncbi.nlm.nih.gov/pubmed/36227895 http://dx.doi.org/10.1371/journal.pone.0276001 |
_version_ | 1784807747382935552 |
---|---|
author | Kondo, Rieko Maeda, Shotaro Kikuchi, Akira Kiyono, Hiromichi Sato, Tohru |
author_facet | Kondo, Rieko Maeda, Shotaro Kikuchi, Akira Kiyono, Hiromichi Sato, Tohru |
author_sort | Kondo, Rieko |
collection | PubMed |
description | Switching inhalation devices is a reasonable option if problems with control, adherence, or inhalation technique occur in patients with asthma treated with inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA). However, evidence to determine the extent to which the carefully monitored period persists after switching is insufficient. In this study, we aimed to investigate the duration of the carefully monitored period after switching to another ICS/LABA. This retrospective study used claims data from Japanese health insurance associations from May 2014 to April 2019. A total of 1,951 patients who switched to another ICS/LABA during the study period were selected for analysis. The relative risk of the first exacerbation after switching was calculated for each four-week interval after the switch compared with that before the switch in a self-controlled case series design. We further assessed patient background associated with exacerbations during the follow-up period. In the primary analysis, the risk of asthma exacerbation compared to the control period was derived from a conditional logistic regression model, which showed a significant decrease immediately after the switch (1 to 4 weeks, Odds ratio [OR] 0.37, 95% confidence interval [CI] 0.26–0.54). Subsequently, the risk increased again and was not significantly different from the control period until week 32 (OR 0.55, 95% CI 0.29–1.04). In a sensitivity analysis among patients with a history of exacerbations, up to week 20 was the period of no continuous risk reduction (OR 0.84, 95% CI 0.41–1.70). In the secondary analysis, chronic rhinosinusitis, sleep disorders, and a history of asthma exacerbation were significantly associated with asthma exacerbation. The incidence of exacerbation remained high for approximately 4 to 7 months after patients with asthma switched to another ICS/LABA. Therefore, these patients should be carefully monitored for at least 4 to 7 months and should be re-assessed at an earlier point in time, if necessary. |
format | Online Article Text |
id | pubmed-9560144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-95601442022-10-14 Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data Kondo, Rieko Maeda, Shotaro Kikuchi, Akira Kiyono, Hiromichi Sato, Tohru PLoS One Research Article Switching inhalation devices is a reasonable option if problems with control, adherence, or inhalation technique occur in patients with asthma treated with inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA). However, evidence to determine the extent to which the carefully monitored period persists after switching is insufficient. In this study, we aimed to investigate the duration of the carefully monitored period after switching to another ICS/LABA. This retrospective study used claims data from Japanese health insurance associations from May 2014 to April 2019. A total of 1,951 patients who switched to another ICS/LABA during the study period were selected for analysis. The relative risk of the first exacerbation after switching was calculated for each four-week interval after the switch compared with that before the switch in a self-controlled case series design. We further assessed patient background associated with exacerbations during the follow-up period. In the primary analysis, the risk of asthma exacerbation compared to the control period was derived from a conditional logistic regression model, which showed a significant decrease immediately after the switch (1 to 4 weeks, Odds ratio [OR] 0.37, 95% confidence interval [CI] 0.26–0.54). Subsequently, the risk increased again and was not significantly different from the control period until week 32 (OR 0.55, 95% CI 0.29–1.04). In a sensitivity analysis among patients with a history of exacerbations, up to week 20 was the period of no continuous risk reduction (OR 0.84, 95% CI 0.41–1.70). In the secondary analysis, chronic rhinosinusitis, sleep disorders, and a history of asthma exacerbation were significantly associated with asthma exacerbation. The incidence of exacerbation remained high for approximately 4 to 7 months after patients with asthma switched to another ICS/LABA. Therefore, these patients should be carefully monitored for at least 4 to 7 months and should be re-assessed at an earlier point in time, if necessary. Public Library of Science 2022-10-13 /pmc/articles/PMC9560144/ /pubmed/36227895 http://dx.doi.org/10.1371/journal.pone.0276001 Text en © 2022 Kondo et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kondo, Rieko Maeda, Shotaro Kikuchi, Akira Kiyono, Hiromichi Sato, Tohru Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data |
title | Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data |
title_full | Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data |
title_fullStr | Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data |
title_full_unstemmed | Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data |
title_short | Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data |
title_sort | optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: a retrospective study using japanese administrative claims data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560144/ https://www.ncbi.nlm.nih.gov/pubmed/36227895 http://dx.doi.org/10.1371/journal.pone.0276001 |
work_keys_str_mv | AT kondorieko optimalfollowupperiodafterswitchingtoanotherinhaledcorticosteroidlongactingb2agonistinpatientswithasthmaaretrospectivestudyusingjapaneseadministrativeclaimsdata AT maedashotaro optimalfollowupperiodafterswitchingtoanotherinhaledcorticosteroidlongactingb2agonistinpatientswithasthmaaretrospectivestudyusingjapaneseadministrativeclaimsdata AT kikuchiakira optimalfollowupperiodafterswitchingtoanotherinhaledcorticosteroidlongactingb2agonistinpatientswithasthmaaretrospectivestudyusingjapaneseadministrativeclaimsdata AT kiyonohiromichi optimalfollowupperiodafterswitchingtoanotherinhaledcorticosteroidlongactingb2agonistinpatientswithasthmaaretrospectivestudyusingjapaneseadministrativeclaimsdata AT satotohru optimalfollowupperiodafterswitchingtoanotherinhaledcorticosteroidlongactingb2agonistinpatientswithasthmaaretrospectivestudyusingjapaneseadministrativeclaimsdata |